Helix BioPharma Corp. Announces Fiscal Second Quarter 2019 Results
March 18, 2019 07:36 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, March 18, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing...
Helix BioPharma Corp. Closes Private Placement, Extends Period to Exercise Warrants and Provides Corporate Update
March 15, 2019 17:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, March 15, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp.: First Patient Dosed in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin
March 07, 2019 17:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, March 07, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates...
Helix BioPharma Corp. and Moffitt Cancer Center to Present at the AACR Annual Meeting 2019 in Atlanta
February 27, 2019 17:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates...
Helix BioPharma Corp. Provides Clinical Development and Strategic Corporate Update
February 11, 2019 07:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates...
Helix BioPharma Corp. Board Changes
February 08, 2019 07:57 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for...
Helix BioPharma Corp. Extends Annual Meeting Date
January 28, 2019 07:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), an immuno-oncology company developing innovative drug candidates for the prevention and...
Helix BioPharma Corp. Closes Final Tranche of Private Placement
December 28, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp. Closes Third Tranche of Private Placement
December 21, 2018 17:06 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp. Closes Second Tranche of Private Placement
December 20, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...